Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A newer version of this guideline has been published: Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer (2024)
- Study type
- Clinical guideline
- Study name
- ESMO Oncogene-addicted mNSCLC 2023
- Design
- ESMO Clinical Practice Guideline
- Source
- Annals of Oncology · 2023
In plain words
This article is an official guideline from the European Society for Medical Oncology (ESMO). It covers the diagnosis, treatment and follow-up of patients with advanced (metastatic) non-small-cell lung cancer whose tumour depends on a specific gene change (an oncogene). The treatment details for each patient should be decided with the treating doctor, based on the results of molecular tests.
Study population
This guideline addresses patients with oncogene-addicted metastatic non-small-cell lung cancer (NSCLC). The PubMed record has no abstract and does not state exact inclusion criteria or the target population; details are in the full text.
Endpoints
This is a guideline, not a trial. The PubMed record has no abstract and does not state endpoints or the guideline development methodology. The title indicates that the guideline covers diagnosis, treatment and follow-up.
Safety and side effects
No information on adverse effects is available in the record. Details are in the full text.
Clinical significance and place in guidelines
The available record has no abstract, so the guideline's specific recommendations, levels of evidence or impact on clinical practice cannot be extracted from it. The guideline was published by the ESMO Guidelines Committee, and the full text should be consulted for each recommendation. Whether it is still current should also be checked against newer ESMO versions.
Limitations
This card is based only on the bibliographic data of the PubMed record; no abstract or recommendation text was available. Before publication, the recommendations and levels of evidence should be extracted from the full text and reviewed by an oncologist.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.